Trust Signals
Written by: FormBlends Medical Team, reviewed against PubMed-indexed literature and FDA regulatory records.
Evidence standard: Every confidence rating in this page is based on study type, sample size, and species. Rodent data is labeled as such. No human approval exists for either compound as of the date of publication.
Conflicts: FormBlends sells research peptides. That financial interest is disclosed. The head-to-head table below concedes where approved alternatives outperform both peptides.
Last reviewed: 2026-05-29
Key Takeaways
- BPC 157 is a 15-amino-acid synthetic peptide (molecular weight 1419.5 Da) with documented pro-angiogenic and tendon-fibroblast effects in rodents. Zero completed human RCTs support its injury-repair use.
- TB 500 is a synthetic fragment of Thymosin Beta-4, a 43-amino-acid protein. TB 500 itself refers to the actin-sequestering fragment Ac-LKKTETQ (roughly 895 Da depending on modifications). WADA explicitly prohibits it in competitive sport.
- Neither compound has an established pharmacokinetic profile in humans. Half-life figures circulating on forums are not sourced from peer-reviewed PK studies.
- The FDA placed BPC 157 on the list of bulk drug substances that may not be used in compounding, effective October 2023, making it unavailable through legitimate compounding pharmacies in the United States.
- Stacking both peptides is widely practiced but has no controlled evidence base, human or animal, supporting the combined protocol.
What Are BPC 157 and TB 500? (Direct Answer)
BPC 157 vs TB 500 represents two structurally unrelated research peptides both investigated for tissue repair. BPC 157 acts primarily through growth-factor receptor upregulation and VEGF signaling. TB 500 works by binding free actin monomers, enabling cell migration into wound beds. Both lack human RCT evidence. They are not interchangeable; their mechanisms are distinct and potentially additive in theory.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What Are BPC 157 and TB 500?
- Mechanism Deep Dive with Specific Numbers
- Evidence Ledger Table
- What Most Pages Get Wrong
- The Chemistry Behind Storage and Stability Rules
- Honest Head-to-Head Table
- Dosing and Operational Label Literacy
- Regulatory and Legal Status
- Known and Theoretical Risks
- FAQ
- Sources
What Are BPC 157 and TB 500 Structurally?
BPC 157 (Body Protection Compound 157) is a pentadecapeptide, meaning 15 amino acids, derived from a portion of the human gastric protein BPC. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is stable in gastric juice, which is physiologically unusual for a peptide, because the central proline-rich region resists protease attack. Molecular weight is 1419.5 Da.
TB 500 is a synthetic fragment, usually the tetrapeptide-extended version Ac-LKKTETQ, derived from the actin-binding domain of Thymosin Beta-4 (TB4), a ubiquitous 43-amino-acid intracellular protein. Full-length TB4 has a molecular weight of roughly 4963 Da. The TB 500 fragment is considerably smaller, in the range of 895 to 900 Da depending on whether it is acetylated, which matters for receptor binding. The fragment retains the actin-sequestering activity of the parent molecule but lacks some of the other immunomodulatory signaling of full-length TB4.
How Do Their Mechanisms Actually Work? (Specific Numbers)
BPC 157
BPC 157's most replicated mechanism in rodent research is upregulation of vascular endothelial growth factor (VEGF) and its receptor VEGFR2 in tendon and gut tissue. Studies from Sikiric et al. (University of Zagreb, published across multiple journals through the 2000s and 2010s) consistently show accelerated tendon-to-bone healing in rat transection models, with histological scores of collagen organization improving over sham-treated controls. In a frequently cited rat Achilles tendon model, tendon strength at 4 weeks post-injury was reported as substantially higher in treated animals versus controls, though "substantially" must stand in for exact numbers here because the measurement protocols varied across publications and direct replication by independent groups is limited.
BPC 157 also modulates the nitric oxide system, upregulates Egr-1 transcription factor (a regulator of tendon-specific collagen genes), and has been shown in cell culture to increase fibroblast migration at concentrations in the nanomolar to low-micromolar range. The caveat: demonstrating a mechanism in isolated fibroblasts does not confirm that the same concentration reaches a tendon in a living human after subcutaneous injection.
TB 500
TB4's actin-sequestering domain (which TB 500 represents) binds G-actin monomers at a 1:1 ratio, reducing the pool available for filament polymerization at the leading edge of resting cells. Paradoxically, this promotes cell migration by redistributing actin dynamics in wound-edge cells. In published in vitro wound-scratch assays, full-length TB4 increases keratinocyte and endothelial cell migration rates by roughly 2- to 3-fold over untreated controls (Malinda et al., Journal of Investigative Dermatology, 1997, n = multiple cell lines). TB4 also downregulates inflammatory mediators including interleukin-1 beta and TNF-alpha in macrophage models.
The honest caveat: TB 500 is a fragment. The published cell-migration data comes almost entirely from full-length TB4. Extrapolating effect size from TB4 to the TB 500 fragment assumes the fragment retains full biological potency, which has not been formally confirmed in parallel dose-response experiments.
Evidence Ledger
| Claim | Best Evidence Type | Species / N | Effect Direction | Confidence |
|---|---|---|---|---|
| BPC 157 accelerates tendon healing | Controlled animal studies (multiple) | Rat, rabbit; dozens of studies, small N per study | Positive, consistent | Low (animal only, limited independent replication) |
| BPC 157 heals gut mucosal damage | Controlled animal studies + one early human oral formulation trial | Rat + small human IBD pilot | Positive in animals; inconclusive in humans | Low |
| TB4 / TB 500 promotes cell migration | In vitro, some animal studies | Cell lines, rodent wound models | Positive | Low (in vitro to human gap is large) |
| TB4 promotes corneal healing (dry eye) | Human clinical trial (Sosne et al.) | Small human pilot | Positive signal | Low to Moderate (very small N, not replicated at scale) |
| BPC 157 + TB 500 stack is superior to either alone | None (mechanism speculation only) | No controlled data | Unknown | Very Low |
| BPC 157 is safe in humans at typical doses | No human safety trial | No data | Unknown | Very Low |
| TB 500 is safe in humans at typical doses | No human safety trial for fragment | No data | Unknown | Very Low |
What Most Pages Get Wrong
The half-life problem. Nearly every forum post and supplement blog states specific half-life figures for BPC 157 (commonly "4 to 6 hours") and TB 500 (commonly "days to weeks"). These numbers are not sourced from published pharmacokinetic studies in humans or, in most cases, even in animals using injected doses. They originate from user speculation that spread into blog content as apparent fact. No peer-reviewed PK study with a named author and DOI has established a plasma half-life for subcutaneously injected BPC 157 in humans. If a page cites a specific half-life figure without a real citation, it fabricated the number or repeated a fabrication.
The fragment vs. parent confusion. Many pages treat TB 500 and Thymosin Beta-4 as interchangeable, citing human wound-healing studies of full-length TB4 as evidence for TB 500. The fragment differs structurally. The actin-binding domain is retained, but full-length TB4's interactions with integrin-linked kinase (ILK) and its nuclear signaling functions may not be replicated by the shorter fragment. Benefit claims for TB4 cannot be directly assigned to TB 500 without fragment-specific dose-response data.
Bioavailability by route. Oral BPC 157 is promoted as equally effective to injectable BPC 157 on many commercial pages. The proline-rich stability is real, meaning BPC 157 resists gastric digestion better than most peptides. However, "not degraded in the stomach" is not the same as "absorbed into systemic circulation at therapeutic concentrations." No bioavailability study comparing oral vs. subcutaneous BPC 157 has been published in humans. Oral claims rest on the gastric stability data plus animal gut-lumen models, not on measured plasma concentrations after oral dosing in a living mammal receiving a therapeutic dose.
The Chemistry Behind Storage and Stability Rules
Both peptides are supplied as lyophilized (freeze-dried) powders. Lyophilization removes water to slow two degradation pathways: hydrolysis (water attacking peptide bonds, breaking the backbone) and oxidative damage (oxygen attacking methionine, cysteine, and tryptophan residues). BPC 157 contains no methionine or cysteine, which makes it more oxidatively stable than many peptides, but hydrolysis and Maillard-type reactions still occur at room temperature over time.
Once you add bacteriostatic water for reconstitution, you reintroduce water and restart hydrolytic degradation. The rate roughly doubles for every 10 degree Celsius increase in temperature, following Arrhenius kinetics. This is why reconstituted solutions should be kept at 2 to 8 degrees Celsius and used within a limited window. The benzyl alcohol in bacteriostatic water slows microbial growth but does not stop chemical degradation of the peptide itself.
Repeated freeze-thaw cycles after reconstitution cause physical aggregation: peptide chains partially unfold, stick together, and form visible or submicron particles. Aggregated peptide is not just less potent; it can, in theory, be immunogenic because aggregated peptide structures can be processed differently by antigen-presenting cells. This is the specific reason single-use aliquots stored at minus 20 degrees Celsius before first use, then kept refrigerated and not refrozen, represent better practice than casual temperature cycling.
Honest Head-to-Head Table
| Parameter | BPC 157 | TB 500 | PRP (Platelet-Rich Plasma) | Corticosteroid Injection |
|---|---|---|---|---|
| Human RCT evidence for tendon repair | None | None | Multiple RCTs (mixed results) | Multiple RCTs (short-term benefit, long-term harm risk) |
| Mechanism understood in humans | No (animal/cell only) | No (animal/cell only) | Yes (growth factor release confirmed) | Yes (anti-inflammatory mechanism confirmed) |
| FDA status | Not approved; banned from compounding (2023) | Not approved | Cleared for some uses (autologous blood product) | Approved drug |
| WADA prohibited | Not currently listed by name (check WADA 2024 list; may fall under peptide hormone class) | Yes, explicitly listed as TB-500 / Thymosin Beta-4 fragment | No (autologous use permitted) | Permitted out-of-competition; TUE required in-competition |
| Safety profile | Unknown in humans | Unknown in humans | Established (autologous, low systemic risk) | Established, with known risks (tendon weakening, metabolic effects) |
| Cost (research grade, typical cycle) | Low to moderate | Low to moderate | High (procedure cost) | Low |
| Gut/IBD evidence | Animal positive, one human pilot (oral PL 14736) | No data | Not applicable | Some (Crohn's / UC, but systemic risks) |
Honest concession: For a patient with a clinically diagnosed rotator cuff tendinopathy who wants the best-evidenced non-surgical option, PRP or an eccentric loading exercise program has more human data than either peptide. These peptides are not appropriate substitutes for established care.
Dosing and Operational Label Literacy
The following reflects protocols observed in the research community. These are not medical recommendations and have no RCT basis in humans.
| Parameter | BPC 157 | TB 500 |
|---|---|---|
| Common research doses cited (not validated) | 200 to 500 mcg per injection, once or twice daily | 2 to 2.5 mg twice weekly in a loading phase; 1 to 2 mg weekly in maintenance |
| Route | Subcutaneous or intramuscular; oral studied in some animal GI models | Subcutaneous or intramuscular |
| Reconstitution solvent | Bacteriostatic water (bacteriostatic saline acceptable) | Bacteriostatic water |
| Typical vial size | 5 mg | 5 mg or 10 mg |
| Reconstitution math example | Add 2 mL bacteriostatic water to 5 mg vial = 2500 mcg per mL. A 250 mcg dose = 0.1 mL on a 1 mL insulin syringe. | Add 2 mL bacteriostatic water to 5 mg vial = 2.5 mg per mL. A 2 mg dose = 0.8 mL. |
| Storage before reconstitution | Minus 20 degrees Celsius or below | Minus 20 degrees Celsius or below |
| Storage after reconstitution | 2 to 8 degrees Celsius; use within weeks | 2 to 8 degrees Celsius; use within weeks |
How to read a COA. A credible certificate of analysis for either peptide should include: (1) HPLC chromatogram showing purity above 98 percent with a single dominant peak, (2) mass spectrometry result matching theoretical molecular weight (BPC 157: 1419.5 Da, TB 500 Ac-LKKTETQ fragment: approximately 895 to 900 Da), (3) endotoxin testing below 1 EU per mg by LAL assay, and (4) water content (Karl Fischer titration) below 6 percent for accurate dosing by weight. A vendor offering only HPLC without mass spec cannot confirm the peptide sequence is correct. A vendor with no endotoxin data carries infection risk that HPLC cannot detect.
Regulatory and Legal Status
In the United States, neither BPC 157 nor TB 500 is an FDA-approved drug. The FDA issued a notice in October 2023 placing BPC 157 on the list of bulk drug substances that may not be used in compounding under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act. This means licensed compounding pharmacies may not legally prepare BPC 157 for patient use. TB 500 has not received this specific designation but also has no approval pathway, and sale for human use violates drug laws.
WADA explicitly lists Thymosin Beta-4 and its fragments, including TB 500, in the Prohibited List under class S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). A competitive athlete testing positive for TB 500 faces the same consequences as any class S2 violation. BPC 157's status under WADA is less explicit by name but may fall under the broader "other growth factors" prohibition depending on interpretation by anti-doping authorities.
Both compounds exist legally in most jurisdictions as research chemicals, meaning they may be purchased for laboratory research but not for human administration. Actual enforcement against individual buyers is rare but the regulatory risk for sellers and prescribers is real and increasing.
Known and Theoretical Risks
Because neither compound has completed human safety trials, the adverse event profile is genuinely unknown. What the existing data suggests:
Pro-angiogenic risk: BPC 157's upregulation of VEGF and VEGFR2 is cited as its healing mechanism. VEGF is also a known driver of tumor vascularization. This does not mean BPC 157 causes cancer, but it means that people with active malignancy, a history of malignancy, or high genetic cancer risk should treat this theoretical concern as disqualifying rather than minor. The same logic applies to TB4 and TB 500, which promote cell migration, a property that is also exploited by metastatic tumor cells.
Injection site reactions: Anecdotally reported across user communities. Without systematic collection these cannot be quantified.
Sourcing contamination: Research-grade peptides are not manufactured under pharmaceutical GMP. Endotoxin contamination from bacterial synthesis byproducts is a real risk with non-GMP peptide manufacturers. Endotoxin injection causes fever, rigors, and in severe cases systemic inflammatory response. This is not a peptide-specific risk; it is a sourcing risk specific to the research chemical market.
FAQ
What is the main difference between BPC 157 and TB 500?
BPC 157 is a 15-amino-acid peptide derived from a gastric protein that primarily signals through growth hormone receptor pathways and acts locally on gut and connective tissue. TB 500 is a synthetic fragment of Thymosin Beta-4 that works by sequestering actin monomers, promoting cell migration across wound beds. Their mechanisms are distinct and potentially complementary, but human trial data is absent for both.
Has BPC 157 been tested in humans?
No published randomized controlled trials in humans exist for BPC 157 as a peptide injection for tissue repair. One oral formulation (PL 14736) was studied in small IBD trials but was not advanced to approval. All injury-repair claims originate from rodent studies.
Has TB 500 been tested in humans?
TB 500 itself has not been tested in published human clinical trials for injury repair. Full-length Thymosin Beta-4 has been explored in small trials for wound healing and dry eye, but TB 500 is a fragment and those results do not transfer directly.
Can BPC 157 and TB 500 be stacked together?
Some practitioners stack both on the premise that BPC 157 supports angiogenesis and tendon fibroblasts while TB 500 drives cell migration, creating additive wound-healing effects. There is no human or controlled animal trial of this specific combination. The safety and interaction profile is entirely unknown.
What is the half-life of BPC 157?
Precise pharmacokinetic data in humans does not exist in the published literature. Rodent studies suggest rapid clearance, with the peptide acting largely at the site of injection rather than systemically. Half-life figures circulating online are not sourced from peer-reviewed pharmacokinetic studies.
What is the half-life of TB 500?
Published half-life data for TB 500 (the fragment) in humans does not exist. Full-length Thymosin Beta-4 has been studied in some pharmacokinetic work in animals, but those figures cannot be reliably extrapolated to the fragment used in the research compound market.
Which peptide is better for tendon injuries?
Rodent studies show BPC 157 accelerates tendon-to-bone healing by upregulating VEGF and collagen synthesis markers. TB 500 rodent studies show improved cell migration and reduced inflammation in soft tissue. Neither has human trial evidence for tendon repair specifically. Platelet-rich plasma has more human evidence and should be considered first.
Are BPC 157 and TB 500 legal?
Neither peptide is FDA-approved as a drug. The FDA has placed BPC 157 on its list of bulk substances that cannot be used in compounding under Section 503A and 503B. TB 500 is not an approved drug. Both are classified as research chemicals in the United States. WADA prohibits Thymosin Beta-4 and its fragments, including TB 500, in competitive sport.
How should BPC 157 and TB 500 be stored?
Both peptides are lyophilized powders that should be stored at or below minus 20 degrees Celsius before reconstitution to minimize hydrolytic and oxidative degradation. After reconstitution in bacteriostatic water, refrigerate at 2 to 8 degrees Celsius and use within days to a few weeks. Repeated freeze-thaw cycles cause aggregation and potency loss.
What purity and testing should a COA show for these peptides?
A credible certificate of analysis should show HPLC purity above 98 percent, mass spectrometry confirmation of the correct molecular weight (BPC 157 is 1419.5 Da, TB 500 varies by fragment but roughly 895 to 900 Da for the common Ac-LKKTETQ fragment), and endotoxin testing below 1 EU per mg. Many vendors supply only HPLC data without mass spec or endotoxin results.
What are the known risks of BPC 157 and TB 500?
Because no human RCTs exist, the full adverse event profile is unknown. BPC 157 animal studies show a generally favorable safety signal at studied doses, but pro-angiogenic activity raises theoretical tumor-promotion concerns. TB 500 shares similar theoretical oncogenic risk from promoting cell migration. Injection-site reactions, nausea, and dizziness are reported anecdotally.
Sources
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract." Current Pharmaceutical Design, 2011. (Representative of the Zagreb group's body of animal work.)
- Sikiric P, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Current Neuropharmacology, 2016.
- Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology, 2011.
- Malinda KM, et al. "Thymosin beta 4 accelerates wound healing." Journal of Investigative Dermatology, 1999.
- Sosne G, et al. "Thymosin beta 4 treatment ameliorates alkali burn ocular surface injuries." Archives of Ophthalmology (now JAMA Ophthalmology), 2002.
- Goldstein AL, Kleinman HK. "Advances in the basic and clinical applications of thymosin beta-4." Expert Opinion on Biological Therapy, 2015.
- U.S. Food and Drug Administration. "Bulk Drug Substances That May Not Be Used in Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act." Federal Register, October 2023. (BPC-157 included.)
- World Anti-Doping Agency. "Prohibited List 2024." WADA, January 2024. (Thymosin Beta-4 and fragments listed under S2.)
- Hannappel E. "beta-Thymosins." Annals of the New York Academy of Sciences, 2010. (Structural review of TB4 and fragments.)
- Crockford D. "Development of thymosin beta4 for treatment of patients with ischemic heart disease." Annals of the New York Academy of Sciences, 2010.
Footer Disclaimers
Platform: FormBlends is an informational and e-commerce platform. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare provider before using any compound described here.
Research Compound Status: BPC 157 and TB 500 are research compounds not approved by the FDA or any comparable regulatory body for human therapeutic use. They are sold for laboratory and research purposes only.
Results: Individual outcomes, if any, are variable and unpredictable. The animal and in vitro evidence described here does not establish that equivalent effects occur in humans.
Trademark: BPC 157 and TB 500 are common-use scientific designations. Thymosin Beta-4 is the name of a naturally occurring protein. FormBlends makes no trademark claim over these terms.